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Utility of Non-Invasive Testing for Fibrosis Assessment 
in Patients with End Stage Renal Disease 
Non-alcoholic fatty liver disease (NAFLD) risk factors (below) have an 
increased prevalence in end stage renal disease (ESRD). 
Characteristic Patient cohort 
(n=171)
Characteristic Patient cohort 
(n=171)
Age 56 years Diabetes 47%
Male 65% Hypertension 96%
Black 60% Dyslipidemia 56%
Non-Hispanic 99% AST (IU/L) 31
BMI 28.9 ALT (IU/L) 29
BMI ≥ 30 36% Platelets x 
103/mL
215
Non-invasive tests Established cut 
offs
Results
Transient 
Elastography (TE)
LS kPa 8.3 (7.1), 6.5 (4.7-8.9)
LS IQR/med 13.2 (5.4)
LS ≥ 9 21%
CAP dB/m 232 (61)
CAP IQR 40 (20)
CAP ≥ 263 dB/m 25%
Probe (M/XL) 62%/38%
AST Platelet Ratio 
Index (APRI)
APRI 0.35 (0.39), 0.025 
(0.016-0.37)
APRI > 1.5 1.8%
Fibrosis-4 Score (FIB-
4)
FIB-4 1.97 (1.33), 0.72 (1.07-
2.37)
FIB-4 > 2.67 15%
Non-alcoholic fatty 
liver disease fibrosis 
score (NFS)
NFS -0.408 (1.61), -0.385 (-
1.56-0.51)
NFS > 0.65 23%
Nikita Chadha, DO; Taseen Syed MBBS, MD; Richard K. Sterling, MD, MSc 
Virginia Commonwealth University, Richmond, Virginia
Retrospective analysis with the demographic, clinical, and laboratory data was 
collected within 12 weeks of TE.
Primary outcomes evaluated for advanced fibrosis (AF, ≥F3) (defined as TE ≥ 9 
kPa) and steatosis (defined as CAP ≥ 263 dB/m).
Univariate and multivariate analysis was performed to identify factors 
associated with AF and steatosis.
In those with available liver histology, utility of LS, FIB-4 and NFS to predict AF 
was assessed. 
BACKGROUND
METHODS
RESULTS DISCUSSION
ACKNOWLEDGEMENTS
May patients with ESRD have normal liver enzymes and therefore do not 
have further testing to evaluate for NAFLD.  Therefore, the prevalence and 
severity of NAFLD in ESRD is unknown.
The goal of study was to assess utility of non-invasive testing (NIT) including 
transient elastography (TE) for liver stiffness (LS), controlled attenuated 
parameter (CAP) for steatosis, Fibrosis-4 (FIB-4), AST to platelet ratio (APRI) 
and NAFLD Fibrosis score (NFS) (Table 1) for assessment of NAFLD in 
patients with ESRD undergoing renal transplant (RT) evaluation. 
Obesity 
(BMI ≥ 30) 
Diabetes 
Mellitus (DM)
Hypertension 
(HTN)
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(DL)
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Table 3. Assessment of each non-invasive test to identify 
advanced fibrosis and steatosis (%, mean (SD), Median (IQR))
Table 2. Demographic and median clinical values of study population
Summary and Conclusions:
- Features of the metabolic syndrome in those presenting for RT evaluation 
are common.
- Despite normal liver enzymes, AF and steatosis were common. 
- NFS identified fibrosis more so than APRI and FIB-4 as it includes 
components of metabolic syndrome in it’s formula.
- It is of utmost importance to identify those patients with advanced fibrosis 
in ESRD as this may help gauge risk of hepatic decompensation post renal 
transplantation. 
- TE and NFS showed good NPV but only moderate ability to predict 
advanced fibrosis à optimal to detect patients who lack significant 
fibrosis.
- Long-term follow-up following RT in this population are needed to 
determine the clinical significance of our findings.
Limitations:
Non-invasive tests may under represent of fibrosis as certain serological 
markers such as AST and ALT may not be elevated in these patients.
Timing of when to perform TE must be considered in the ESRD population 
(post-HD is preferred so that volume will not interfere with results).
Future Directions:
Multi-center study to further stratify a more global consensus with regards to a 
preferred modality of testing across all ethnicities. 
Only 14 patients in this study had biopsies available for correlation; may 
benefit from further correlation with biopsies.
Non-invasive tests Formula
APRI [(AST/normal AST)/platelet count (103/mL)] x 100
FIB-4 [age(years) x AST)/(platelet count (103/mL)) x Ö ALT]
NFS -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 
1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 ×
AST/ALT ratio – 0.013 × platelet (×109/L) – 0.66 ×
albumin (g/dL)
Table 1. Formulas for Selected Non-Invasive Tests
- Comorbidities of metabolic syndrome were common with HTN being the 
most prevalent followed by DM and DL (Table 2).
- AF and steatosis were observed in 21% and 25%, respectively (Table 3). 
- Patients with steatosis were found to have higher BMI (p < 0.0001) and 
obesity (p < 0.001). 
- NFS showed reasonable accuracy to detect AF, however, did not 
correlate with TE in identifying fibrosis.
• Non-alcoholic fatty liver disease (NAFLD) risk factors (below) have an increased prevalence in end stage 
renal disease (ESRD). 
– Obesity (BMI ≥ 30) 
– Diabetes Mellitus (DM)
– Hypertension (HTN)
– Dyslipidemia (DL)
• May patients with ESRD have normal liver enzymes and therefore do not have further testing to evaluate 
for NAFLD.  Therefore, the prevalence and severity of NAFLD in ESRD is unknown.
• The goal of study was to assess utility of non-invasive testing (NIT) (see below; Table 1) for assessment of 
NAFLD in patients with ESRD undergoing renal transplant (RT) evaluation.
– Transient elastography (TE) for liver stiffness (LS)
– Controlled attenuated parameter (CAP) for steatosis
– Fibrosis-4 (FIB-4)
– AST to platelet ratio (APRI)
– NAFLD Fibrosis score (NFS)
Introduction/Background
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Methods
• Retrospective analysis with the demographic, clinical, and laboratory data was collected within 12 weeks of 
TE.
• Primary outcomes evaluated for advanced fibrosis (AF, ≥F3) (defined as TE ≥ 9 kPa) and steatosis (defined 
as CAP ≥ 263 dB/m).
• Univariate and multivariate analysis was performed to identify factors associated with AF and steatosis.
• In those with available liver histology, utility of LS, FIB-4 and NFS to predict AF was assessed. 
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Non-invasive tests Formula
APRI [(AST/normal AST)/platelet count (103/mL)] x 100
FIB-4 [age(years) x AST)/(platelet count (103/mL)) x Ö ALT]
NFS -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 
1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT 
ratio – 0.013 × platelet (×109/L) – 0.66 × albumin (g/dL)
Table 1. Formulas for Selected Non-Invasive Tests
Results
• Comorbidities of metabolic syndrome were common with HTN being the most prevalent followed by DM and 
DL (Table 2).
• AF and steatosis were observed in 21% and 25%, respectively (Table 3). 
• Patients with steatosis were found to have higher BMI (p < 0.0001) and obesity (p < 0.001). 
• NFS showed reasonable accuracy to detect AF, however, did not correlate with TE in identifying fibrosis.
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Results
Table 2. Demographic and median clinical values of 
study population
Table 3. Assessment of each non-invasive test to 
identify advanced fibrosis and steatosis (%, mean 
(SD), Median (IQR))
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Characteristic Patient 
cohort 
(n=171)
Characteristic Patient 
cohort 
(n=171)
Age 56 years Diabetes 47%
Male 65% Hypertension 96%
Black 60% Dyslipidemia 56%
Non-Hispanic 99% AST (IU/L) 31
BMI 28.9 ALT (IU/L) 29
BMI ≥ 30 36% Platelets x 
103/mL
215
Non-invasive 
tests
Established cut offs Results
Transient 
Elastography 
(TE)
LS kPa 8.3 (7.1), 6.5 (4.7-8.9)
LS IQR/med 13.2 (5.4)
LS ≥ 9 21%
CAP dB/m 232 (61)
CAP IQR 40 (20)
CAP ≥ 263 dB/m 25%
Probe (M/XL) 62%/38%
AST Platelet 
Ratio Index 
(APRI)
APRI 0.35 (0.39), 0.025 (0.016-
0.37)
APRI > 1.5 1.8%
Fibrosis-4 Score 
(FIB-4)
FIB-4 1.97 (1.33), 0.72 (1.07-
2.37)
FIB-4 > 2.67 15%
Non-alcoholic 
fatty liver disease 
fibrosis score 
(NFS)
NFS -0.408 (1.61), -0.385 (-
1.56-0.51)
NFS > 0.65 23%
Discussion and Conclusion
• Features of the metabolic syndrome in those presenting 
for RT evaluation are common.
• Despite normal liver enzymes, AF and steatosis were 
common. 
• NFS identified fibrosis more so than APRI and FIB-4 as it 
includes components of metabolic syndrome in it’s 
formula.
• It is of utmost importance to identify those patients with 
advanced fibrosis in ESRD as this may help gauge risk of 
hepatic decompensation post renal transplantation. 
• TE and NFS showed good NPV but only moderate ability 
to predict advanced fibrosis à optimal to detect 
patients who lack significant fibrosis.
• Long-term follow-up following RT in this population are 
needed to determine the clinical significance of our 
findings.
Limitations:
• Non-invasive tests may under represent of fibrosis as 
certain serological markers such as AST and ALT may not 
be elevated in these patients.
• Timing of when to perform TE must be considered in the 
ESRD population (post-HD is preferred so that volume 
will not interfere with results).
Future Directions:
Multi-center study to further stratify a more global consensus 
with regards to a preferred modality of testing across all 
ethnicities. 
Only 14 patients in this study had biopsies available for 
correlation; may benefit from further correlation with 
biopsies.
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